Cargando…

Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity

[Image: see text] Alterations in visceral adipose tissue (VAT) are closely linked to cardiometabolic abnormalities. The aim of this work is to define a metabolic signature in VAT of insulin resistance (IR) dependent on, and independent of, obesity. An untargeted UPLC-Q-Exactive metabolomic approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Palau-Rodriguez, Magalí, Marco-Ramell, Anna, Casas-Agustench, Patricia, Tulipani, Sara, Miñarro, Antonio, Sanchez-Pla, Alex, Murri, Mora, Tinahones, Francisco J., Andres-Lacueva, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631729/
https://www.ncbi.nlm.nih.gov/pubmed/33760621
http://dx.doi.org/10.1021/acs.jproteome.0c00918
_version_ 1784607621280432128
author Palau-Rodriguez, Magalí
Marco-Ramell, Anna
Casas-Agustench, Patricia
Tulipani, Sara
Miñarro, Antonio
Sanchez-Pla, Alex
Murri, Mora
Tinahones, Francisco J.
Andres-Lacueva, Cristina
author_facet Palau-Rodriguez, Magalí
Marco-Ramell, Anna
Casas-Agustench, Patricia
Tulipani, Sara
Miñarro, Antonio
Sanchez-Pla, Alex
Murri, Mora
Tinahones, Francisco J.
Andres-Lacueva, Cristina
author_sort Palau-Rodriguez, Magalí
collection PubMed
description [Image: see text] Alterations in visceral adipose tissue (VAT) are closely linked to cardiometabolic abnormalities. The aim of this work is to define a metabolic signature in VAT of insulin resistance (IR) dependent on, and independent of, obesity. An untargeted UPLC-Q-Exactive metabolomic approach was carried out on the VAT of obese insulin-sensitive (IS) and insulin-resistant subjects (N = 11 and N = 25, respectively) and nonobese IS and IR subjects (N = 25 and N = 10, respectively). The VAT metabolome in obesity was defined among other things by changes in the metabolism of lipids, nucleotides, carbohydrates, and amino acids, whereas when combined with high IR, it affected the metabolism of 18 carbon fatty acyl-containing phospholipid species. A multimetabolite model created by glycerophosphatidylinositol (18:0); glycerophosphatidylethanolamine (18:2); glycerophosphatidylserine (18:0); and glycerophosphatidylcholine (18:0/18:1), (18:2/18:2), and (18:2/18:3) exhibited a highly predictive performance to identify the metabotype of “insulin-sensitive obesity” among obese individuals [area under the curve (AUC) 96.7% (91.9–100)] and within the entire study population [AUC 87.6% (79.0–96.2)]. We demonstrated that IR has a unique and shared metabolic signature dependent on, and independent of, obesity. For it to be used in clinical practice, these findings need to be validated in a more accessible sample, such as blood.
format Online
Article
Text
id pubmed-8631729
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-86317292021-12-01 Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity Palau-Rodriguez, Magalí Marco-Ramell, Anna Casas-Agustench, Patricia Tulipani, Sara Miñarro, Antonio Sanchez-Pla, Alex Murri, Mora Tinahones, Francisco J. Andres-Lacueva, Cristina J Proteome Res [Image: see text] Alterations in visceral adipose tissue (VAT) are closely linked to cardiometabolic abnormalities. The aim of this work is to define a metabolic signature in VAT of insulin resistance (IR) dependent on, and independent of, obesity. An untargeted UPLC-Q-Exactive metabolomic approach was carried out on the VAT of obese insulin-sensitive (IS) and insulin-resistant subjects (N = 11 and N = 25, respectively) and nonobese IS and IR subjects (N = 25 and N = 10, respectively). The VAT metabolome in obesity was defined among other things by changes in the metabolism of lipids, nucleotides, carbohydrates, and amino acids, whereas when combined with high IR, it affected the metabolism of 18 carbon fatty acyl-containing phospholipid species. A multimetabolite model created by glycerophosphatidylinositol (18:0); glycerophosphatidylethanolamine (18:2); glycerophosphatidylserine (18:0); and glycerophosphatidylcholine (18:0/18:1), (18:2/18:2), and (18:2/18:3) exhibited a highly predictive performance to identify the metabotype of “insulin-sensitive obesity” among obese individuals [area under the curve (AUC) 96.7% (91.9–100)] and within the entire study population [AUC 87.6% (79.0–96.2)]. We demonstrated that IR has a unique and shared metabolic signature dependent on, and independent of, obesity. For it to be used in clinical practice, these findings need to be validated in a more accessible sample, such as blood. American Chemical Society 2021-03-24 2021-05-07 /pmc/articles/PMC8631729/ /pubmed/33760621 http://dx.doi.org/10.1021/acs.jproteome.0c00918 Text en © 2021 American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Palau-Rodriguez, Magalí
Marco-Ramell, Anna
Casas-Agustench, Patricia
Tulipani, Sara
Miñarro, Antonio
Sanchez-Pla, Alex
Murri, Mora
Tinahones, Francisco J.
Andres-Lacueva, Cristina
Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity
title Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity
title_full Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity
title_fullStr Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity
title_full_unstemmed Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity
title_short Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity
title_sort visceral adipose tissue phospholipid signature of insulin sensitivity and obesity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631729/
https://www.ncbi.nlm.nih.gov/pubmed/33760621
http://dx.doi.org/10.1021/acs.jproteome.0c00918
work_keys_str_mv AT palaurodriguezmagali visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT marcoramellanna visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT casasagustenchpatricia visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT tulipanisara visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT minarroantonio visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT sanchezplaalex visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT murrimora visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT tinahonesfranciscoj visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity
AT andreslacuevacristina visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity